Obu Health Review
Best for: Cost-conscious patients seeking a multi-product compounded-peptide platform (GLP-1 plus NAD+/sermorelin add-ons) with named 503A pharmacy transparency and a published LegitScript ID, who are comfortable contacting support for per-dose pricing and state eligibility.
Obu Health (obuhealth.com) is a Las Vegas-based multi-product telehealth platform operated by OBU Health LLC (10845 Griffith Peak Dr. Ste 200, Las Vegas, NV 89135) offering compounded semaglutide from $190/month and compounded tirzepatide from $239/month, plus NAD+ injections ($219) and sermorelin ($149). The platform is LegitScript-certified (ID 44206977) and fulfills prescriptions through two named pharmacy partners — Manifest Pharmacy (Greer, SC) and RX Compounding Store (Miami, FL). Live-verified 2026-05-15: ships US-only with state-by-state therapy restrictions; some states require live chat or video consultation, others use async questionnaire review with response within 24 hours.
Medium confidence · Last verified 2026-05-15 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Obu Health is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
Obu Health prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Starting price (subscription) | compounded | $190 |
| Starting price (subscription) | compounded | $239 |
| Add-on peptide | compounded | $219 |
| Add-on peptide sermorelin | compounded | $149 |
✓ Pros
- •LegitScript-certified with publicly displayed ID (44206977)
- •Two named 503A compounding-pharmacy partners (Manifest Pharmacy SC + RX Compounding Store FL) — transparency above category baseline
- •Lower advertised semaglutide starting price ($190) than most multi-product peer platforms
- •Multi-product offering (GLP-1s + NAD+ + sermorelin + generic ED + birth control) for single-platform users
- •24-hour US board-certified physician response window
✗ Cons
- •Per-dose pricing tiers not transparently published on product pages — only 'starting from' prices visible
- •No explicit state-coverage list disclosed; FAQ confirms restrictions exist 'based on state' without enumeration
- •Medical director not named publicly
- •No published consultation fee disclosure — unclear whether physician visit is included in medication price
- •All sales final per FAQ ('Federal and State law do not allow medication returns')
- •Subscription auto-renewal/cancellation mechanics minimally documented
Ready to start with Obu Health?
Starting at $149/month. See current pricing and start your free consultation.
Sources & methodology
Our Obu Health review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Obu Health
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with Obu Health?
Starting at $149/month. See current pricing and start your free consultation.